和黃醫藥獲霸菱亞洲投資基金1億美元股權投資
和黃醫藥(HCM.US)公布與霸菱亞洲投資基金達成一項最終協議,通過定向增發向霸菱亞洲的關聯基金發行1億美元新股,發行價相當於每股美國存托股份30.5美元。
和黃醫藥首席執行官賀雋指,隨著愛優特和蘇泰達的上市銷售等,預計今年業務將會取得顯著增長,正在迅速擴展全部由和黃醫藥自主發現的十種創新腫瘤藥物的全球開發,並計劃於2021年內啟動8至10項註冊和註冊意向研究,歡迎霸菱亞洲成為公司的股東。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.